Tonix Pharmaceuticals Holding Corp. · NASDAQ:TNXP

Tonix Pharmaceuticals — Corporate Update (November 2020)

17 slides from Tonix Pharmaceuticals's corporate update, Nov 2, 2020

  1. Slide 1: TNX-1800: Horsepox-Vector Based Potential COVID-19 Vaccine

    © 2020 Tonix Pharmaceuticals Holding Corp. 1 October 2020 NASDAQ: TNXP Version P0252 (Doc 0725) TNX - 1800: Horsepox - Vector Based Potential COVID - 19 Vaccine

  2. Slide 2: Cautionary Note on Forward-Looking Statements

    © 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are “forward - looking statements” as defined by the Private Securities Litigat

  3. Slide 3: Seth Lederman, MD

    © 2020 Tonix Pharmaceuticals Holding Corp. 3 Seth Lederman, MD Currently, CEO of Tonix Pharmaceuticals, Dr. Lederman began his career in research in the early days of the AIDS crisis and studied the entry of HIV into cells at the molecular and cell biological levels. Dr. Lederman is a co - inventor

  4. Slide 4: Vaccine Landscape

    © 2020 Tonix Pharmaceuticals Holding Corp. 4 COVID - 19 Vaccine Landscape • More than 150 vaccines in development • Diversity of approaches is important since protective immunity is not yet understood • Technologies range from never tested before to 220 years old • Uncertainty exists around efficacy

  5. Slide 5: Live Attenuated Virus Vaccines for Other Infectious Diseases

    © 2020 Tonix Pharmaceuticals Holding Corp. 5 Live Attenuated Virus Vaccines for Other Infectious Diseases 1 • Long term, durable immunity • Stimulate T cells and provide years to decades of protection • Single administration, scalable manufacturing • Low dose is amplified by replication, mRNA and pr

  6. Slide 6: TNX-1800: Potential Vaccine Engineered for Long-term Immunity

    © 2020 Tonix Pharmaceuticals Holding Corp. 6 TNX - 1800 1 : Potential COVID - 19 Vaccine Engineered for Long - term Immunity • Based on “vaccinia” vaccine developed more than 200 years ago by Dr. Edward Jenner to prevent smallpox • Eradicated smallpox (only viral disease ever eradicated) • Elicits d

  7. Slide 7: Vaccinia Induces a Skin Reaction Called "Take"

    © 2020 Tonix Pharmaceuticals Holding Corp. 7 Vaccinia Induces a Skin Reaction Called “Take” – Described by Dr. Edward Jenner 1. Fulginiti VA, et al. Clin Infect Dis. 2003;37(2):241 - 250. 2. Liu L, et al. Nature Med. 2010;16(2):224 - 228. 3. Centers for Disease Control and Prevention. Accessed April

  8. Slide 8: TNX-1800, a SARS-CoV-2 Vaccine Candidate

    © 2020 Tonix Pharmaceuticals Holding Corp. 8 TNX - 1800 1 , a SARS - CoV - 2 Vaccine Candidate • Utilizes Tonix’s proprietary horsepox virus as a vector • Encodes a protein from SARS - CoV - 2, the cause of COVID - 19 • Developed in collaboration with University of Alberta, Canada • Animal testing w

  9. Slide 9: Why Use a Horsepox Platform for a Vaccine?

    © 2020 Tonix Pharmaceuticals Holding Corp. 9 Why Use a Horsepox Platform for a Vaccine? Horsepox can be engineered to express foreign genes • Lack of persistence or genomic integration in the host • Strong immunogenicity as a vaccine • Readily manufacture at scale • Live, attenuated vaccine – direct

  10. Slide 10: TNX-1800 Upcoming Milestones

    © 2020 Tonix Pharmaceuticals Holding Corp. 10 TNX - 1800 Upcoming Milestones Southern Research studies will address two key questions: • Will vaccination of animals elicit an immune response to the S protein? • 4th Quarter 2020 – Non - human primate and small animal response results expected 1 • Wil

  11. Slide 11: Unique Challenges of SARS-CoV-2

    © 2020 Tonix Pharmaceuticals Holding Corp. 11 Unique Challenges of SARS - CoV - 2 SARS - CoV - 2 is more infectious, has a longer incubation time, and presents asymptomatically in more individuals, making it highly spreadable 1 The death rate for COVID - 19 is significantly lower compared to SARS. 1

  12. Slide 12: Contrasting T cell and Antibody Immunity

    © 2020 Tonix Pharmaceuticals Holding Corp. 12 Contrasting T cell and Antibody Immunity • T cell immunity • Durable or long - lived (many years) • Recognize fragments of pathogens on the surfaces of infected cells • Cannot recognize pathogens directly • Potential to clear viral infections (by killing

  13. Slide 13: What Is the Goal of Vaccination?

    © 2020 Tonix Pharmaceuticals Holding Corp. 13 What Is the Goal of Vaccination? • Vaccination instructs the immune system how to respond rapidly upon reinfection 1 - 3 • A typical infection is a race between the virus and the immune response • Vaccination gives the body a “head start” • Most vaccines

  14. Slide 14: Reason for Optimism?

    © 2020 Tonix Pharmaceuticals Holding Corp. 14 COVID - 19: Reason for Optimism? • Most people recover, which suggests: • Vaccines can be designed that safely mimic infection • Herd immunity can be achieved by vaccination • Vaccine developers can learn from individuals who recover • Study their immuni

  15. Slide 15: Where Do We Go From Here?

    © 2020 Tonix Pharmaceuticals Holding Corp. 15 Where Do We Go From Here? • Goal: Effective COVID - 19 vaccines • So we can return to work and school • Need #1 Quickly available vaccines • Even if they offer only temporary immunity -- several now in human trials • Need #2 Vaccines providing long - ter

  16. Slide 16: Upcoming Milestones of TNX-1800 Program

    © 2020 Tonix Pharmaceuticals Holding Corp. 16 Upcoming Milestones of TNX - 1800 Program 1 © 2020 Tonix Pharmaceuticals Holding Corp. • Results from small animal and non - human primate studies, including challenge with SARS - CoV - 2, due 4Q 2020 2 • 4 th Quarter 2020 – Small animal and primate immu

  17. Slide 17: Thank You!

    © 2020 Tonix Pharmaceuticals Holding Corp. 17 Thank You!

Tonix Pharmaceuticals Holding — Corporate Update (November 2020) on 6ix